JANX Janux Therapeutics Inc
655
$47.12
$0.02
(0.04%)
| Watchers | 655 |
| 52-Wk Low | $5.65 |
| 52-Wk High | $65.60 |
| Market Cap | $2.44B |
| Volume | 581,042.00 |
| 52-Wk High | $65.60 |
| 52-Wk Low | $5.65 |
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbPR Newswire • 11 days ago
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
Share to Feed
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
read more...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday's session.
read more...
Investors eyeing a purchase of Janux Therapeutics Inc (JANX) shares, but tentative about paying the going market price of 35.70/share, might benefit from considering selling puts among the...
Investors might want to bet on Janux Therapeutics, Inc. (JANX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which...
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX Get Free Report) have been assigned a consensus rating of Buy from the six analysts that are covering the firm, MarketBeat...
Cantor Fitzgerald assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX Free Report) in a research report sent to investors on Wednesday, MarketBeat reports. The firm issued an...
Investment analysts at BTIG Research started coverage on shares of Janux Therapeutics (NASDAQ:JANX Get Free Report) in a research report issued on Thursday, Marketbeat reports. The brokerage...